Biology and Function of Tumor-Associated Trypsin Inhibitor, Tati

References

• Stenman U-H, Huhtala M-L, Koistinen R, Seppälä M. Immunochemical demonstration of an ovarian cancer associated urinary peptide. Int J Cancer 1982; 30: 53–7
   PubMed Web of Science ®Google Scholar
• Huhtala M-L, Pesonen K, Kalkkinen N, Stenman U-H. Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 1982; 257: 13713–6
   PubMed Web of Science ®Google Scholar
• Kazal L A, Spicer D S, Brahinsky R AA. Isolation of a crystalline trypsin inhibitor-anticoagulant protein from pancreas. J Amer Chem Soc 1948; 70: 3034–40
   PubMed Web of Science ®Google Scholar
• Tomita N, Horii A, Yamamoto T, Ogawa M, Mori T, Matsubara K. Expression of pancreatic secretory trypsin inhibitor gene in neoplastic tissues. FEBS Lett 1987; 225: 113–9
   PubMedGoogle Scholar
• von Fritz H, Müller I, Wiedemann M, Werle E. Zur Chemie und Physiologie der spezifischen Trypsininhibitoren aus den Bauchspei-cheldriisen von Rind, Hund, Schwein und Mensch. Hoppe-Seyler's Z Physiol Chem 1967; 348: 405–18
   PubMedGoogle Scholar
• Halila H, Lehtovirta P, Stenman U-H. Tumor-associated trypsin inhibitor in ovarian cancer. Br J Cancer 1988; 57: 304–7
   PubMed Web of Science ®Google Scholar
• Koivunen E, Saksela O, Itkonen O, Osman S, Huhtala M-L, Stenman U-H. Human colon carcinoma, fibrosarcoma and leukemia cell lines produce tumor-associated trypsinogen. Int J Cancer 1991; 47: 592–6
   PubMed Web of Science ®Google Scholar
• Koivunen E, Ristimäki A, Itkonen O, Osman S, Vuento M, Stenman U-H. Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. Cancer Res 1991; 51: 2107–12
   PubMed Web of Science ®Google Scholar
• Tomita N, Doi S, Higashiyama M, Morimoto H, Murotani M, Kawasaki Y, et al. Expression of pancreatic secretory trypsin inhibitor gene in human colorectal tumor. Cancer 1990; 66: 2144–9
   PubMedGoogle Scholar
• Bohe M, Lindström C, Ohlsson K. Immunohis-tochemical demonstration of pancreatic secretory proteins in human Paneth cells. Scand J Gastroenterol 1986; 21: 65–8, suppl 126
   Web of Science ®Google Scholar
• Freeman T, Playford R, Quinn C, Beardshall K, Poulter L, Yuoung J, Calam J. Pancreatic secretory trypsin inhibitor in gastrointestinal mucosa and gastric juice. Gut 1990; 31: 1318–23
   PubMed Web of Science ®Google Scholar
• Higashiyama M, Monden T, Ogawa M, Matsuu-Ra N, Murotani M, Kawasaki Y, et al. Immuno-histochemical study of pancreatic secretory trypsin inhibitor in gastric carcinomas. Am. J. Clin. Pathol 1990; 93: 8–13
   PubMedGoogle Scholar
• Shibata T, Ogawa M, Matsuda K, Miyauchi K, Yamamoto T, Mori T. Purification and characterization of pancreatic secretory trypsin inhibitor in human gastric mucosa. Clin Chim Acta 1986; 159: 27–36
   PubMedGoogle Scholar
• Huhtala M-L, Kahanpää K, Seppälä M, Halila H, Stenman U-H. Excretion of a tumor associated trypsin inhibitor (TATI) into urine of patients with gynecological malignancy. Int J Cancer 1983; 31: 711–4
   PubMed Web of Science ®Google Scholar
• Kolho K-L, Huhtala M-L, Jalanko H, Rauramo I, Stenman U-H. Pancreatic secretory trypsin inhibitor from human amniotic fluid and fetal and neonatal urine: concentrations and physico-chemical characterization. Clin Chim Acta 1986; 156: 123–30
   PubMedGoogle Scholar
• Haglund C, Huhtala M-L, Halila H, Nordling S, Roberts P, Scheinin T, Stenman U-H. tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary disease. Brit J Cancer 1986; 54: 297–303
   PubMedGoogle Scholar
• Matsuda K, Ogawa M, Murata A, Kitahara T, Kosaki G. Elevation of serum immunoreactive pancreatic secretory trypsin inhibitor contents in various malignant diseases. Res Commun Chem Pathol Pharmacol 1983; 40: 301–5
   PubMedGoogle Scholar
• Mogensen O, Mogensen B, Jakobsen A. Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumors. Br J Cancer 1990; 61: 327–329
   PubMed Web of Science ®Google Scholar
• Stenman U-H. Tumour-associated trypsin inhibitor and tumour associated trypsin. Scand J Clin Lab Invest 1990; 50: 93–101, Suppl 201
   Google Scholar
• Huhtala M-L. Demonstration of a new acrosin inhibitor in human seminal plasma. Hoppe-Seyler's Z Physiol Chem 1984; 365: 819–25
   PubMedGoogle Scholar
• Turpeinen U, Koivunen E, Stenman U-H. Reaction of a tumor-associated trypsin inhibitor with serine proteases involved in tumor invasion. Biochem J 1988; 254: 911–4
   PubMedGoogle Scholar
• Pubols M H, Bartelt D C, Greene LJ. Trypsin inhibitor from human pancreas and pancreatic juice. J Biol Chem 1974; 249: 2235–42
   PubMed Web of Science ®Google Scholar
• Koivunen E, Itkonen O, Stenman U-H. Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2. Cancer Res 1990; 50: 2375–78
   PubMed Web of Science ®Google Scholar
• Hunt L T, Barker W C, Dayhoff MO. Epidermal growth factor: Internal duplication and probable relationship to pancreatic secretory trypsin inhibitor. Biochem Biophys Res Comm 1974; 60: 1020–8
   PubMedGoogle Scholar
• Kikuchi N, Nagata K, Yoshida N, Ogawa M. The multiplicity of human pancreatic secretory trypsin inhibitor. J Biochem 1985; 98: 679–94
   Google Scholar
• Ogawa M, Tsushima T, Ohba Y, Ogawa N, Tanaka S, Ishida M, Mori T. Stimulation of DNA synthesis in human fibroblasts by human pancreatic seceretory trypsin inhibitor. Res Commun Chem Pathol Pharmacol 1985; 50: 155–8
   PubMedGoogle Scholar
• McKeehan W L, Sakagami Y, Hoshi H, McKeehan KA. Two apparent human endothelial cell growth factors from human hepatoma cells are tumor-associated proteinase inhibitors. J Biol Chem 1986; 261: 5378–83
   PubMed Web of Science ®Google Scholar
• Niinobu T, Ogawa M, Shibata T, Murata A, Ni-Shibe S, Mori T, Ogata N. Specific binding of human pancreatic secretory trypsin inhibitor to various cultured cells. Res Commun Chem Pathol Pharmacol 1986; 53: 245–8
   PubMedGoogle Scholar
• Stenman U-H, Koivunen E, Itkonen O, Turpeinen U, Halila H, Huhtala M-L. Tumor-associated trypsin inhibitor, TATI. Clinical use and biological function. Ann Chir Gynaecol Fenn 1989; 78: 77–82
   Google Scholar
• Horii A, Kobayashi T, Tomita N, Yamamoto T, Fukushige S, Murotsu T., Ogawa M, et al. Primary structure of human pancreatic secretory trypsin inhibitor (PSTI) gene. Biochem Biophys Res Comm 1987; 149: 635–41
   PubMedGoogle Scholar
• Sporn M B, Roberts AB. Peptide growth factors and inflammation, tissue repair, and cancer. J Clin Invest 1986; 78: 329–32
   PubMed Web of Science ®Google Scholar
• Koivunen E, Huhtala M-L, Stenman U-H. Human ovarian tumor-associated trypsin. Its purification from mucinous cyst fluid and identification as an activator of pro-urokinase. J Biol Chem 1989; 264: 14095–9
   PubMed Web of Science ®Google Scholar
• Lasson Å, Borgström A, Ohlsson K. Elevated pancreatic secretory trypsin inhibitor levels during severe inflammatory disease, renal insufficiency, and after various surgical procedures. Scand J Gastroenterol 1986; 21: 1275–80
   PubMed Web of Science ®Google Scholar
• Ogawa M, Matsuura N, Higashiyma K, Mori T. Expression of pancreatic secretory trypsin inhibitor in various cancer cells. Res Commun Chem Pathol Pharmacol 1987; 55: 137–40
   PubMedGoogle Scholar
• Halila H, Huhtala M-L, Haglund C, Nordling S, Stenman U-H. Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA. Br J Cancer 1987; 56: 153–6
   PubMed Web of Science ®Google Scholar
• Kitahara T, Takatsuka Y, Fujimoto K-I, Tanaka S, Ogawa M, Kosaki K. Radioimmunoassay for human pancreatic secretory trypsin inhibitor: Measurement of serum pancreatic secretory trypsin inhibitor in normal subjects and subjects with pancreatic diseases. Clin Chim Acta 1980; 103: 135–43
   PubMed Web of Science ®Google Scholar
• Matsuda K, Ogawa M, Shibata T, Nishibe S, Miyauchi K, Matsuda Y, Mori T. Postoperative elevation of serum pancreatic secretory trypsin inhibitor. Am J Gastroenterol 1985; 80: 694–8
   PubMed Web of Science ®Google Scholar
• Ogawa M, Matsuda K, Shibata T, Matsuda Y, Ukai T, Ohta M, Mori T. Elevation of serum pancreatic secretory trypsin inhibitor (PSTI) in patients with serious injury. Res Commun Chem Pathol Pharmacol 1985; 50: 259–66
   PubMedGoogle Scholar
• Ogawa M. Pancreatic secretory trypsin inhibitor as an acute phase reactant. Clin Biochem 1988; 21: 19–25
   PubMed Web of Science ®Google Scholar
• Kido H, Yokogoshi Y, Katunuma N. A low-molecular mass Kazal-type protease inhibitor isolated from rat hepatocytes is identical to rat pancreatic secretory trypsin inhibitor II. Purification and amino acid sequence. Eur J Biochem 1990; 188: 501–6
   Google Scholar
• Murata M, Ogawa M, Uda K-I, Matsuura N, Watanabe Y, Baba T, et al. Release of pancreatic secretory trypsin inhibitor from human hepatoblastoma cells on stimulation with cytokines. Life Sci 1988; 43: 1233–40
   PubMedGoogle Scholar
• Yamamoto T, Nakamura Y, Nishide T, Emi M, Ogawa M, Mori T, Matsubara K. Molecular cloning and nucleotide sequence of human pancreatic secretory trypsin inhibitor (PSTI) cDNA. Biochem Biophys Res Commun 1985; 132: 605–12
   PubMedGoogle Scholar
• Barbey-Morel C, Pierce J A, Campbell DH. Lip-opolysacharide modulates the expression of alpha 1 proteinase inhibitor and other proteinase inhibitors in human monocytes and macrophages. J Exp Med 1987; 166: 104–54
   Google Scholar
• Paavonen J, Lehtinen M, Lehto M, Laine S, Aine R, Räsänen L, Stenman U-H. Concentrations of tumor-associated trypsin inhibitor and C-reactive protein in serum in pelvic inflammatory disease. Clin Chem 1989; 35: 869–71
   PubMed Web of Science ®Google Scholar
• Stenman U-H, Koivunen E, Vuento M. Characterization of a tumor-associated serine protease. Biol Chem Hoppe-Seyler 1988; 369: 9–14
   PubMedGoogle Scholar
• Emi M, Nakamura Y, Ogawa M, Yamamoto T, Nishide T, Mori T, Matsubara K. Cloning, characterization and nucleotide sequences of two cDNAs encoding human pancreatic trypsino-gens. Gene 1986; 41: 305–10
   PubMed Web of Science ®Google Scholar
• Itkonen O, Koivunen E, Hurme M, Alfthan H, Schröder T, Stenman U-H. Time-resolved im-munofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of tryp-sinogen-2 in pancreatitis. J Lab Clin Med 1990; 115: 712–718
   PubMed Web of Science ®Google Scholar
• Mignatti P, Robbins E, Rifkin B. Tumor invasion through the human amniotic membrane: requirement for a protease cascade. Cell 1986; 47: 487–98
   PubMed Web of Science ®Google Scholar
• Danø K, Andreasen P A, Gröndahl-Hansen J, Kristensen P, Nielsen L S, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139–266
   PubMed Web of Science ®Google Scholar
• Liotta L A, Rao C N, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983; 49: 636–49
   PubMed Web of Science ®Google Scholar
• Tryggvason K, Höyhtyä M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987; 907: 191–217
   PubMed Web of Science ®Google Scholar